Asia Pacific Viscosupplementation Market

APAC Viscosupplementation Market Size (2023 to 2028)

The size of the APAC viscosupplementation market is forecasted to grow at a CAGR of 11.44% between 2023 to 2028 and be worth USD 1.93 billion by 2028 from USD 1.12 billion in 2023.

The rising population suffering from osteoarthritis is propelling the viscosupplementation market in APAC. In China, a significant portion of the aged people are suffering from knee OA and the prevalence is almost up to 22% in men and 43% in women. Most people feel continuous pain in their knees, leading to osteoarthritis. This condition is common in the joints of the knees, hands, feet, and hips and affects the spine and shoulder with growing age. It is a type of degenerative bone disease that is mainly seen in older populations over 65 years of age. According to the National Library of Medicine, 12.4% of the total population in the Asia-Pacific is of more than 60 years and nearly half of the older population suffers from osteoarthritis in this region. Viscosupplementation is one of the effective treatment procedures to reduce the pain in joints for patients by injecting a thick fluid named hyaluronate into the knee joints.

Furthermore, most people prefer non-surgical treatment for osteoarthritis. Many patients cannot opt for surgical procedures in the treatment of knee pains since the patient needs to meet certain health guidelines to be approved for surgery. As a result, the patients who do not match the criteria prefer injection-based treatment at regular intervals to reduce pain and increase the mobility of the body parts, which drives the APAC viscosupplementation market forward.

Technical advancements in viscosupplementation treatment are another major factor accelerating the market growth. There are several treatments for knee pain in the region among which Hyaluronic acid, which is used in viscosupplementation treatment to reduce knee pain and swelling, is the most advanced treatment in this region. Several clinical trials are being conducted on the medicine injected into the knees to give more relief with fewer side effects. In addition, most researchers are working on developing an advanced treatment for this knee disorder so that older people can walk freely.

However, the high costs associated with the viscosupplementation treatment procedures and the side effects linked are a few of the factors hampering the market growth in the Asia-Pacific region. Strict government policies for using viscosupplementation treatment in some areas also hamper the market growth. The need for more skilled professionals in giving the treatment also impedes market growth. The dearth of researchers is a major problem faced when increasing the production of this drug as a smaller number of people for the research results in slower drug development and product launch which could in turn hamper the development of treatments.

This market research report on the APAC viscosupplementation market has been segmented and sub-segmented into the following categories.

By Product:

• Single Injection
• Three Injection
• Five Injection

By End-Use:

• Hospitals
• Orthopedic Clinic/ Ambulatory Surgical Centers (ASCs)

By Country:

• India
• China
• Japan
• South Korea
• Australia
• New Zealand
• Thailand
• Malaysia
• Vietnam
• Philippines
• Indonesia
• Singapore
• Rest of APAC

Geographically, Asia Pacific is the fastest growing region in the global market and is expected to register a substantial share of the market during the forecast period owing to the increasing population preferring viscosupplementation treatment in this region. The prevalence of osteoarthritis is growing consistently in the Asia-Pacific region. The changing lifestyles of the people, including food habits, are causing the persistence of pain in the knee and joints in a large population from this region. Unhealthy food habits are another major cause that can lead to joint pains. Increasing obesity also results in osteoarthritis disease in many people. Depending upon the person's fluid levels in the joints, the dosage at intervals of 1 week, three weeks, or six months will be decided.

The Chinese viscosupplementation market is forecasted to account major chunk of the APAC regional market share during the forecast period. The growing number of people suffering from rheumatoid arthritis and the rising demand for non-surgical treatments for osteoarthritis are propelling the viscosupplementation market in China.

The Indian viscosupplementation market is one of the fastest-growing regions in the APAC regional market. Growing demand for ambulatory surgeries, increasing awareness around viscosupplementation in India and rising aging population are boosting the market growth in India.

During the forecast period, the viscosupplementation market in Japan is projected to grow at a healthy CAGR. In Japan, most of the younger patients are choosing this treatment. Due to the acceptance of intra-articular hyaluronic acid in the treatment of joints problem in this region, the market has a significant share. The availability of this medicine in online stores and near medical stores also drives the market forward. Launching of new products by many key players and the approvals of medicine for pain relief, joint problems, and knee problems also help market growth.

KEY MARKET PARTICIPANTS:

A few of the noteworthy companies dominating the APAC viscosupplementation market analyzed in this report are Sanofi S.A., Zimmer Biomet Holdings Inc., Bioventus LLC, Anika Therapeutics Inc., Fidia Farmaceutici S.p.A., Ferring B.V., Seikagaku Corporation, Chungai Pharmaceutical Co., Ltd., OrthogenRx Inc., and Mylan N.V.